MetaCap

Alvotech (ALVO)

NASDAQ: ALVOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

4.12-0.17 (-3.96%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ALVO stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.82
52-week range
2.94 – 6.53
Day range
4.09 – 4.29
Volume / Avg
826.57K / 1.13M
Beta
—

52-week range

$2.94$6.53

ALVO stock today

Shares of Alvotech (ALVO) finished lower on Nov 20 at $4.12, a drop of 3.96% or $0.17 per share, versus the S&P 500's 3.70% decline. At this level, ALVO sits in the middle of its 52-week range of $2.94 to $6.53: 36.9% below the high, set on Oct 5, 2026 and 40.1% above the low. ALVO is down 19.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 19.8%.

Alvotech has posted a net loss over the last twelve months (EPS of -$0.82), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Alvotech

Company profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Ms. Lisa Graver
Headquarters
Luxembourg
Employees
1,279

Financial highlights

Full financials

In fiscal 2025, Alvotech generated $586.3 million in revenue, up 19.7% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $27.9 million, for a net margin of 4.8% versus a median of -276.0% in the prior 5 years. Gross margin was 59.8% (down from 62.2%) and operating margin 13.3%.

Alvotech annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$586.32M$489.68M$91.43M$83.03M$36.77M
Growth+19.74%+435.56%+10.12%+125.79%-44.80%
Net income$27.92M$-231.86M$-551.73M$-513.58M$-101.50M
EPS (diluted)$0.10$-0.87$-2.43$-2.60$-0.92

Analyst forecast

Forecast

Consensus (7 analysts)

buy

Avg. price target

$7.50+82.04%

  • Strong buy 2
  • Buy 4
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $9.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.02 vs $-0.01
Surprise
-100.00%

ALVO news

All ALVO news

Alvotech peers

Health Care sector
ALVO peer companies
CompanyPrice% ChgMarket capCompare
WWBWindward Bio Group AG24.29+1.15%$1.45Bvs ALVO
MESOMesoblast Limited ADR10.89-2.59%$1.41Bvs ALVO
RXRXRecursion Pharmaceuticals Inc. Class A2.45-9.93%$1.53Bvs ALVO
VIRVir Biotechnology Inc.8.39-5.41%$1.56Bvs ALVO
IMCRImmunocore Holdings plc ADR26.41-0.83%$1.36Bvs ALVO
NVAXNovavax Inc.7.47-3.24%$1.23Bvs ALVO
MAZEMaze Therapeutics Inc.31.37-3.27%$1.72Bvs ALVO
LYCALycia Therapeutics Inc.33.07+4.09%$1.72Bvs ALVO

Indexes, lists and sector

Alvotech stock FAQ

What is Alvotech's stock price today?

ALVO last traded at $4.12 as of Nov 20, 4:00 PM EST, down 3.96% on the day. Prices are delayed at least 15 minutes.

Who is Alvotech's CEO?

Ms. Lisa Graver is the chief executive officer of Alvotech, which has about 1,279 employees.

What is the ALVO 52-week high?

The 52-week high for ALVO is $6.53 and the 52-week low is $2.94. The stock is currently 36.9% below its high.

Compare ALVO